863505-04-8

Basic information

• Product Name: 1H-Pyrazole-1-carboxylic acid, 3-[[3-hydroxy-5-[(1S)-2-methoxy-1-methylethoxy]benzoyl]amino]-, 1,1-dimethylethyl ester
• CAS NO: 863505-04-8
• Molecular Formula: C19H25N3O6
• Molecular Weight: 391.424
• Mol File: 863505-04-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-1-carboxylic acid, 3-[[3-hydroxy-5-[(1S)-2-methoxy-1-methylethoxy]benzoyl]amino]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-1-carboxylic acid, 3-[[3-hydroxy-5-[(1S)-2-methoxy-1-methylethoxy]benzoyl]amino]-, 1,1-dimethylethyl ester(863505-04-8)
• EPA Substance Registry System: 1H-Pyrazole-1-carboxylic acid, 3-[[3-hydroxy-5-[(1S)-2-methoxy-1-methylethoxy]benzoyl]amino]-, 1,1-dimethylethyl ester(863505-04-8)

Safety Data

• Hazardous Substances Data: 863505-04-8(Hazardous Substances Data)

Upstream product

• 851885-41-1 3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]benzoic acid 
• 863504-84-1 3-aminopyrazole-1-carboxylic acid tert-butyl ester 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 851885-42-2 methyl 3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]benzoate 
• 863505-05-9 1,1-dimethylethyl 3-[({3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]phenyl}carbonyl)amino]-1H-pyrazole-1-carboxylate 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 

Downstream Products

• 863505-06-0 ethyl 3-fluoro-4-{3-[(1S)-2-methoxy-1-methylethoxy]-5-[(1H-pyrazol-3-ylamino)carbonyl]phenoxy}benzoate 
• 863505-03-7 tert-butyl 3-({3-[4-(ethoxycarbonyl)phenoxy]-5-[(1S)-2-methoxy-1-methylethoxy]benzoyl}amino)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

-

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.